99 related articles for article (PubMed ID: 18320840)
1. Role of cyclooxygenase-2 in tumor progression and immune regulation in lung cancer.
Patel S; Chiplunkar S
Indian J Biochem Biophys; 2007 Dec; 44(6):419-28. PubMed ID: 18320840
[TBL] [Abstract][Full Text] [Related]
2. Multifaceted roles of cyclooxygenase-2 in lung cancer.
Riedl K; Krysan K; Põld M; Dalwadi H; Heuze-Vourc'h N; Dohadwala M; Liu M; Cui X; Figlin R; Mao JT; Strieter R; Sharma S; Dubinett SM
Drug Resist Updat; 2004 Jun; 7(3):169-84. PubMed ID: 15296859
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
Mutter R; Lu B; Carbone DP; Csiki I; Moretti L; Johnson DH; Morrow JD; Sandler AB; Shyr Y; Ye F; Choy H
Clin Cancer Res; 2009 Mar; 15(6):2158-65. PubMed ID: 19276291
[TBL] [Abstract][Full Text] [Related]
4. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
[TBL] [Abstract][Full Text] [Related]
5. Inflammation and lung carcinogenesis: applying findings in prevention and treatment.
Peebles KA; Lee JM; Mao JT; Hazra S; Reckamp KL; Krysan K; Dohadwala M; Heinrich EL; Walser TC; Cui X; Baratelli FE; Garon E; Sharma S; Dubinett SM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1405-21. PubMed ID: 17944566
[TBL] [Abstract][Full Text] [Related]
6. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
Crawford J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
[TBL] [Abstract][Full Text] [Related]
7. [The prognostic effect of natural killer cell infiltration to tumoral tissues in stage I non-small cell lung cancer].
Karadayi S; Kayi Cangir A; Ozturk S; Dizbay Sak S; Akal M; Akay H
Tuberk Toraks; 2008; 56(3):251-6. PubMed ID: 18932025
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of proline-rich tyrosine kinase 2 in non-small cell lung cancer.
Zhang S; Qiu X; Gu Y; Wang E
Lung Cancer; 2008 Dec; 62(3):295-301. PubMed ID: 18571765
[TBL] [Abstract][Full Text] [Related]
9. Multiple roles of cyclooxygenase-2 in endometrial cancer.
Ohno S; Ohno Y; Suzuki N; Inagawa H; Kohchi C; Soma G; Inoue M
Anticancer Res; 2005; 25(6A):3679-87. PubMed ID: 16302726
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu.
Ren XL; Xu YM; Bao W; Fu HJ; Wu CG; Zhao Y; Li ZK; Zhang J; Li SQ; Chen WQ; Wang T; Zhang R; Zhang LH; Qian GS; Chen SY; Jia LT; Yang AG
Cancer Lett; 2009 Aug; 281(2):134-43. PubMed ID: 19339104
[TBL] [Abstract][Full Text] [Related]
12. S100A2 induces metastasis in non-small cell lung cancer.
Bulk E; Sargin B; Krug U; Hascher A; Jun Y; Knop M; Kerkhoff C; Gerke V; Liersch R; Mesters RM; Hotfilder M; Marra A; Koschmieder S; Dugas M; Berdel WE; Serve H; Müller-Tidow C
Clin Cancer Res; 2009 Jan; 15(1):22-9. PubMed ID: 19118029
[TBL] [Abstract][Full Text] [Related]
13. Prostaglandin E2 stimulates human lung carcinoma cell growth through induction of integrin-linked kinase: the involvement of EP4 and Sp1.
Zheng Y; Ritzenthaler JD; Sun X; Roman J; Han S
Cancer Res; 2009 Feb; 69(3):896-904. PubMed ID: 19176380
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer.
Carrillo de Santa Pau E; Arias FC; Caso Peláez E; Muñoz Molina GM; Sánchez Hernández I; Muguruza Trueba I; Moreno Balsalobre R; Sacristán López S; Gómez Pinillos A; del Val Toledo Lobo M
Cancer; 2009 Apr; 115(8):1701-12. PubMed ID: 19197998
[TBL] [Abstract][Full Text] [Related]
15. Multitargeted inhibitors in lung cancer: new clinical data.
Bar J; Herbst RS; Onn A
Clin Lung Cancer; 2008; 9 Suppl 3():S92-9. PubMed ID: 19419930
[TBL] [Abstract][Full Text] [Related]
16. Updates in non-small cell lung cancer.
Walker S
Clin J Oncol Nurs; 2008 Aug; 12(4):587-96. PubMed ID: 18676326
[TBL] [Abstract][Full Text] [Related]
17. IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities.
Ho MY; Leu SJ; Sun GH; Tao MH; Tang SJ; Sun KH
J Immunol; 2009 Nov; 183(10):6217-26. PubMed ID: 19841177
[TBL] [Abstract][Full Text] [Related]
18. Anti-survivin antibody responses in lung cancer.
Karanikas V; Khalil S; Kerenidi T; Gourgoulianis KI; Germenis AE
Cancer Lett; 2009 Sep; 282(2):159-66. PubMed ID: 19380192
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention of lung cancer: from concept to reality.
van Zandwijk N
Rocz Akad Med Bialymst; 2003; 48():5-10. PubMed ID: 14737934
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic strategy for treatment of metastatic non-small cell lung cancer.
Berhoune M; Banu E; Scotte F; Prognon P; Oudard S; Bonan B
Ann Pharmacother; 2008 Nov; 42(11):1640-52. PubMed ID: 18957625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
